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MOULDING THE 
SURGICAL MIND
William Hunter, 18th-century 
obstetrician and medical educator, 
once described surgeons as “savages 
with knives”. Ironically, one of these 
savages, his brother John, became 
one of surgery’s icons. In their time, 
patients were pinned down, screaming 
and squirming, by burly assistants, 
and the surgeon’s fame rested on his 
dexterity, precision and speed. Then, 
surgeons were feared, surgery was 
limited in frequency and scope, 
and plagued by deadly sepsis.
The arrivals of anaesthesia, 
antisepsis and asepsis changed all that. 
Now, surgeons are revered, surgery’s 
scope is virtually unlimited, and 
waiting list numbers swell. 
But what is the image of the 
modern surgeon?
In their recent review, Surgeons and 
cognitive processes, Australian surgeons 
John Hall and Jeffrey Hamdorf and 
educator Carleen Ellis focus on this 
image. Surgery continues to be a male-
dominated fraternity of adherents of 
resolute action, aggression, technology 
and defensive detachment in practice. 
Their expertise is bound up in 
experience, and entry into their ranks is 
influenced by sex and an “intolerance 
of ambiguity, excessive reliance on high 
technology, a negative orientation 
towards psychological problems and 
a Machiavellianism...expressed as 
‘the means justifies the end’ or 
‘whatever it takes’.” 
But Hall and his colleagues believe 
that something is missing in the 
moulding of surgical minds — an 
emphasis on analysis, problem-solving, 
evaluation, discrimination and 
judgement. In short, surgeons’ training 
is short on thinking, reasoning and 
understanding. The call by Hall and 
colleagues to move the focus from 
action to reflection is not new. 
Eminent US surgeon William J Mayo 
once observed that “Surgery is more 
a matter of mental grasp than it 
is of handicraftsmanship.” 
Stressing this mental grasp requires 
a seismic shift in surgery’s culture.
Martin B Van Der Weyden
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Letters
How much cervical cancer 
is being prevented?
Heather S Mitchell
Medical Director, Victorian Cervical Cytology Registry, 
PO Box 161, Carlton South, VIC 3053. 
Heather.Mitchell@vccr.org
TO THE EDITOR: It was estimated in
1989 t at cervical screening in Australia
was preventing only 46% of squamous
malignancies, against a theoretical
capacity of 90%.1 This suboptimal
achievement after almost 25 years of
cervical screening led to a major reor-
ganisation of the program.
The 1989 analysis has been repeated,
using the most recent year (1998) for
which incidence rates have been pub-
lished (Box). The more recent figures
suggest that cervical screening in Aus-
tralia is now preventing 70% of squa-
mous carcinoma of the cervix.
This remarkable improvement can
probably be attributed to the improved
participation by women in regular
screening, improved standards within
laboratories, and better follow-up of
cytological abnormalities. While there is
still scope for improvement, there is
clear evidence of a substantially better
gain from cervical screening. Continued
efforts to increase the participation rate
among women aged 60–69 years is
appropriate given that the prevented
proportion appears to be lower in this
age range.
1. Australian Health Ministers' Advisory Council. Cervical Can-
cer Screening Evaluation Committee. Cervical cancer
screening in Australia: Options for change. Australian Insti-
tute of Health: Prevention Program Evaluation Series No 2.
Canberra: AGPS, 1991.
2. Australian Bureau of Statistics 1998. Estimated resident
population by age and sex: Australian States and Territo-
ries, June 1997 to June 1998. Canberra: ABS, 1998.
(Catalogue No. 3201.0.)
3. Australian Bureau of Statistics 2001. National Health Survey.
Canberra: ABS, 2001. (Catalogue No. 4364.0.)
4. Day NE. The epidemiological basis for evaluating different
screening policies. In: Hakama M, Miller AB, Day NE.
Screening for cancer of the uterine cervix. Lyon: Interna-
tional Agency for Research on Cancer, 1996: 199-209.
5. Australian Institute of Health and Welfare (AIHW). Cervical
screening in Australia 1997-1998. Canberra: AIHW, 2000.❏
Ethics and research 
participation
Simon C Gandevia
Professor and NHMRC Senior Principal Research 
Fellow, Prince of Wales Medical Research Institute, 
Randwick, Barker Street, Randwick, NSW 2031; and 
Member, Human Research Ethics Committee, 
University of New South Wales.
s.gandevia@unsw.edu.au
TO THE EDITOR: The recent article by
Scott and colleagues1 described a retro-
spective analysis by postal questionnaire
of the attitudes of family members to
participation (about a year earlier) in a
face-to-face interview about their child’s
diagnosis of Ewing’s sarcoma. This was
accompanied by an editorial exposing
the complexities of research participa-
tion, including the potential risks of
interviews as well as the role of altruism.2
Although results derived from the
questionnaire have only recently been
published (November 2002), the ques-
tionnaire was distributed in November
1997, before introduction of the
National statement on the ethical conduct
of research involving humans.3 Some ethi-
cal uncertainties and questions of his-
torical interest arise. First, what was the
nature of the original consent obtained
for the initial interviews? Presumably it
involved written informed consent in
which the risks of participation were
clearly mentioned, including the possi-
bility of distress associated with the
interview. Did it mention a procedure
for aborting or complaining about the
interview? Second, did the patients
(aged up to about 35 years) and their
families give permission to be contacted
again by the same research group?
Third, for the follow-up on research
participation, was consent implied sim-
ply by return of the questionnaire?
Finally, how would the conduct of the
initial interviews and the follow-up
questionnaire differ in the light of recent
developments in the ethics of research
involving humans?
Importantly, the respondents (84% of
those surveyed) indicated that partici-
pation in the original study had not
“upset them”.1 While the attitude of
non-responders is unknown, this would
LETTERS
Percentage of squamous carcinoma of the cervix prevented, by age group, Australia 1998
Age group
Number of women 
(estimated number with 
a cervix*) in Australia2
Expected rate (per 100000 










20–24 665 691 (665 025) 5 33.3 9.6 71.1%
25–29 733 145 (732 412) 15 109.9 34.8 68.3%
30–34 706 925 (687 838) 25 172.0 62.9 63.4%
35–39 748 913 (728 692) 45 327.9 74.7 77.2%
40–44 702 629 (608 477) 45 273.8 76.2 72.2%
45–49 649 539 (562 501) 45 253.1 81.4 67.8%
50–54 570 287 (410 607) 45 184.8 48.1 74.0%
55–59 431 183 (310 452) 45 139.7 40.7 70.9%
60–64 370 123 (251 314) 45 113.1 40.7 64.0%
65–69 348 707 (236 772) 45 106.6 44.4 58.3%
Total 5 927 142 (5 194 090) 1714 514 70.0%
*Calculated by multiplying the number of women in Australia by the estimated age-specific hysterectomy fractions.3 †Methodology as for the study by the International 
Agency for Research on Cancer,4 using incidence in Norway at a time when the rates would have been little affected by screening. ‡Calculated by multiplying the 
estimated number of women in Australia with a cervix by the expected rate of squamous carcinoma of the cervix in the absence of screening.4 §Calculated by 
multiplying the number of cases of cervical cancer observed in 1998 by 0.74, which was the proportion of all cervical cancers that were squamous.5
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seem to confirm that the original proc-
ess had been sensitive and appropriate.
This is supported by the finding that
families whose child had died after the
initial interview were more likely to
respond to the questionnaire.
As a long-time member of a university
human research ethics committee, I
have often been required to evaluate
research protocols that involve poten-
tially threatening or distressing inter-
views. This has occurred more
frequently since introduction of the
National statement, as much qualitative
research previously conducted under
different jurisdictions (such as quality
control or clinical audit) has been sub-
mitted for formal ethical review. The
risk of harm to participants in qualita-
tive research cannot be trivialised. Its
impact can be minimised by wording
the consent form to warn of possible
adverse psychological reactions to inter-
views and questionnaires, using trained
interviewers and providing counselling
support if needed.
1. Scott DA, Valery PC, Boyle FM, Bain CJ. Does research into
sensitive areas do harm? Experiences of research partici-
pation after a child’s diagnosis with Ewing’s sarcoma. Med J
Aust 2002; 177: 507-510.
2. Braunack-Mayer A. The ethics of participating in research.
Med J Aust 2002; 177: 471-472.
3. National Health and Medical Research Council. National
statement on the ethical conduct of research involving
humans. Canberra: NHMRC, 1999. ❏
A Quality Use of Medicines 
program for continuity of care 
in therapeutics from hospital 
to community
Joseph J Gelb
Senior Partner, Hospital Pharmacy Services, 
262 Mountain Highway, Wantirna, VIC 3152 
silverback@skibuff.com
TO THE EDITOR: The article by Mant et
al1 and the letters following its publica-
tion focus attention on a long-standing
problem that, despite concerted efforts
by governments, healthcare providers
and other stakeholders to address it,
remains a major obstacle to effective and
appropriate continuity of pharmacother-
apy following discharge from hospital.
There is little doubt that many of the
difficulties arise as a result of poor
communication between hospitals and
general practitioners. This is further
exacerbated by a lack of standard proto-
cols for the preparation and dissemina-
tion of discharge summaries. Nowhere
is this more evident than in the case of
residents of aged-care facilities return-
ing from hospital with radically changed
medication regimens.
To establish appropriate communica-
tion channels, Mant et al mention hospi-
tal GP liaison officers.1 New canvasses
the potential problems and suggests sen-
sible solutions, including the involve-
ment of community pharmacists.2
However, every hospital has a ready-
made resource that requires only a set of
formal protocols and procedures to
make it function — clinical pharmacists.
Clinical pharmacists view every
patient’s chart at least once every day.
The chart not only provides information
for dispensing, but also gives pharma-
cists an opportunity to monitor Quality
Use of Medicines and communicate
with hospital doctors regarding existing
or potential problems.
By the time the “prescription” is
processed and the medication dis-
pensed, quality issues have been
addressed and a detailed record created.
From the dispensing record, a “medica-
tion profile” could be generated This
can provide the patient with consumer
information regarding each drug, its
dose, frequency of administration and
mode of action, and can act as an
accurate and up-to-date discharge sum-
mary. In addition, a clear, legible copy
can be faxed, mailed or electronically
transmitted to the patient’s GP, phar-
macist, specialist, allied healthcare pro-
fessional, rehabilitation hospital or
aged-care facility.
Our organisation provides medication
management services to a large number
of aged-care facilities as well as to public
and private hospitals, and correctional
facilities. Quality Use of Medicines
monitoring constitutes a vital part of
our clinical pharmacists’ duties. It pro-
vides an effective, accurate and timely
method of communicating detailed dis-
charge summaries (which have under-
gone thorough Qual i ty  Use of
Medicines screening) to GPs and other
interested parties.
By including hospital clinical pharma-
cists in the Quality Use of Medicines
monitoring and evaluation process,
meaningful information can be
obtained, appropriate judgements
made, effective communication con-
ducted and optimum pharmacotherapy
outcomes achieved.
1. Mant A, Kehoe L, Cockayne NL, et al. A Quality Use of
Medicines program for continuity of care in therapeutics
from hospital to community. Med J Aust 2002; 177: 32-34.
2. New PW. A Quality Use of Medicines program for continuity
of care in therapeutics from hospital to community [letter].
Med J Aust 2002; 177: 575. ❏
Karen I Kaye,* Andrea Mant,† Linda Kehoe,‡ 
Wendy C Rotem§
* Executive Officer, NSW Therapeutic Assessment 
Group Inc, Sydney, NSW; †Quality Use of Medicines 
Services, South East Sydney Area Health Service, 
Level 5, 376 Victoria Street, Darlinghurst, NSW 2010; 
‡Consultant, Total Research, Sydney, NSW; 
§Consultant, Health Services Project Management, 
Sydney, NSW. a.mant@unsw.edu.au
IN REPLY: Gelb points out that clinical
pharmacists can, and in some cases do,
provide useful communication to gen-
eral practitioners following hospitalisa-
tion, as well as for their patients in aged
care facilities. Regrettably, clinical phar-
macists are in short supply, even in
teaching hospitals; thus, in practice,
their expertise often cannot be fully
utilised.1 Attention to this shortage is
clearly warranted to safeguard patient
care.
We agree that clinical pharmacists
(hospital and community based) should
be included in the Quality Use of Medi-
cines monitoring and evaluation proc-
ess. In addition, we urge all healthcare
Correspondents
We prefer to receive letters by email (editorial@ampco.com.au). Letters must be no 
longer than 400 words and must include a word count. All letters are subject to editing. 
Proofs will not normally be supplied. There should be no more than 4 authors per letter. 
Each author should provide current qualifications and position and full details of postal 
address, telephone and facsimile numbers.
There should be no more than 5 references. The reference list should not include 
anything that has not been published or accepted for publication. Reference details 
must be complete, including: names and initials for up to 4 authors, or 3 authors et al if 
there are more than 4 (see mja.com.au/public/information/uniform.html#refs for how to 
cite references other than journal articles).
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providers to take responsibility for care-
ful and timely communication to ensure
continuity of patient care.
1. Kaye KI, Mant A, Brien JE, Kehoe L. Evaluation of the
implementation and effectiveness of the Australian Pharma-
ceutical Advisory Council (APAC) national guidelines to
achieve the continuum of quality use of medicines between
hospital and the community. Report to the Commonwealth
Department of Health and Ageing. October 2002. ❏
Clinical practice guidelines 
for depression in 
young people
Jon N Jureidini,* Anne L Tonkin†
*Child Psychiatrist, and Head, Department of 
Psychological Medicine, Women’s and Children's 
Hospital, 72 King William Road, North Adelaide, SA 
5006; †Clinical Pharmacologist and Associate 
Professor, Department of Clinical and Experimental 
Pharmacology, University of Adelaide, Adelaide, SA
jureidini@healthyskepticism.org
TO THE EDITOR: We would like to
comment on a recent article by Chan et
al on clinical practice guidelines for
depression in young people.1 We disa-
gree with their proposal to amend
National Health and Medical Research
Council (NHMRC) guidelines2 to
include a statement that “SSRIs [selec-
tive serotonin reuptake inhibitors], par-
ticularly fluoxetine and paroxetine,
should also be considered as a first-line
treatment” for major depression in
young people. We believe that there is
insufficient evidence to assign a grade of
“E1”2 to this statement. Chan et al1
quote three randomised controlled trials
(RCTs) and one systematic review in
support of their argument, but as yet the
results of only two of the three RCTs
have been published.3,4 Unfortunately,
Chan et al do not include a critical
appraisal of the significant methodolog-
ical and analytical problems with each
of the studies. Nor is any comment
made about risk–benefit ratios, or the
fact that even if the results were sound
the clinical relevance of such small dif-
ferences between active drug and pla-
cebo is questionable.5 The following
brief commentary on the two studies
highlights the dangers of carrying out
sophisticated procedures such as meta-
analysis without sufficient attention to
the quality of the trials included in the
analysis.
The very high dropout rates (46% of
48 for placebo; 29% of 48 for fluoxet-
ine) in the study by Emslie et al3 raise
questions about the reliability of the
results. Other interpretations of the
findings are plausible. For example, in
their study, significant advantage to
fluoxetine over placebo on the Clinical
Global Impressions improvement rating
(a primary outcome measure) was lost
when only patients completing the trial
were counted (P = 0.2).
More worrying is that Chan and col-
leagues do not seem to have noticed the
dangerously distorted reporting in the
study by Keller et al.4 On neither of the
two designated primary outcome meas-
ures (change from baseline in Hamilton
Rating Scale for Depression [HAM-D],
and response, set as “fall in HAM-D to
 8 or by  50%”) did paroxetine differ
significantly from placebo. But Keller
and colleagues never report this nega-
tive finding. Instead, the criteria for
response are covertly altered (to “fall in
HAM-D to  8”, which does achieve
significance). The authors then errone-
ously claim significance on this (altered)
primary outcome measure, ignoring the
lack of significant change. Thus, a study
that showed no significant improvement
on either of two primary outcome meas-
ures is reported as demonstrating
unqualified efficacy.
Similar problems can be found in a
more recent article by Emslie and
colleagues6 (published after the review
by Chan et al1), in which the authors
openly acknowledge that the difference
between fluoxetine and placebo on their
prospectively defined primary outcome
measure did not reach statistical signifi-
cance, yet claim to have demonstrated
the drug’s efficacy.
Another worry is that Chan and col-
leagues, in their list of proposed changes
to NHMRC recommendations,1 sug-
gest that the availability of SSRIs obvi-
ates the need for more expert and
thoughtful assessment and management
of depression. We are uncomfortable
that the prescribing and management of
psychotropic medication is portrayed as
requiring relatively few skills and
resources, to be carried out by those
general practitioners who lack training
in mental health and/or access to expert
mental health services.
We urge the NHMRC to maintain a
conservative approach to the use of
psychotropic drugs in children with
depression unless more convincing evi-
dence is forthcoming.
1. Chan RTW, Rey JM, Hazell PL. Clinical practice guidelines
for depression in young people: are the treatment recom-
mendations outdated? Med J Aust 2002; 177: 448-451.
2. National Health and Medical Research Council. Depression
in young people: clinical practice guidelines. Canberra:
Australian Government Publishing Service, 1997.
3. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind,
randomized, placebo-controlled trial of fluoxetine in chil-
dren and adolescents with depression. Arch Gen Psychia-
try 1997; 54: 1031-1037.
4. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine
in the treatment of adolescent major depression: a rand-
omized, controlled trial. J Am Acad Child Adolesc Psychia-
try 2001; 40: 762-772.
5. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emperor’s
new drugs: an analysis of antidepressant medication data
submitted to the U.S. Food and Drug Administration. Pre-
vention & Treatment 2002; Vol. 5, Article 23. Available at:
ht tp: / /www.journals.apa.org/prevent ion/volume5/
pre0050023a.html (accessed Jan 2003).
6. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine
for acute treatment of depression in children and adoles-
cents: a placebo-controlled, randomized clinical trial. J Am
Acad Child Adolesc Psychiatry 2002; 41: 1205-1215. ❏
Raphael T W Chan,* Joseph M Rey,† 
Philip L Hazell‡
*Child Psychiatrist, †Professor and Director, Child and 
Adolescent Mental Health Services, Northern Sydney 
Health, NSW; ‡Director and Conjoint Professor, Child 
and Youth Mental Health Services, Hunter Area 
Health, NSW
rchan@doh.health.nsw.gov.au
IN REPLY: We thank Jureidini and
Tonkin for their comments. In relation
to their criticism of the study by Emslie
et al,1 intention-to-treat analysis is the
accepted standard. In relation to the
study by Keller et al,2 their criticism
about the criteria for response has
already been answered elsewhere. (Cri-
teria were defined in the report as a final
Hamilton Rating Scale for Depression
[HAM-D] score that was  8 or a
reduction from baseline of  50%. Dual
criteria were selected because the scores
at entry could range from a minimum of
12 [set by protocol] to a maximum of
53 [highest scores for the 17-item
HAM-D]. Limiting response to either a
50% reduction or a specified cut-off
point would impede patients at the
lower end of the ranges from meeting
the criterion.3) The concern about the
absence of differences in change scores
on the HAM-D cannot be resolved, as
mean change in scores and standard
errors of the means were not reported.
However, 63.3% (57/90) of subjects
taking paroxetine (P = 0.02 versus pla-
cebo) achieved a HAM-D total score of
 8 at endpoint. With respect to the size
of difference in response rate to active
treatment versus placebo, the results of
trials involving selective serotonin
reuptake inhibitors (SSRIs) in children
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and adolescents are similar to those
reported in adults (ie, SSRIs achieve a
response in about 20% more partici-
pants than placebo,4 which is similar to
the 26% difference between cognitive
behavioural therapy and various control
conditions5). Consistent with these
results, the US Food and Drug Admin-
istration has recently approved fluoxet-
ine to treat children and adolescents
aged seven to 17 years for major depres-
sion. We believe that there are sufficient
new treatment data (including a study,6
published since the submission of our
article, showing fluoxetine’s superiority
over placebo in symptom improvement
and in remission rates) to warrant revi-
sion of the 1997 guidelines.
Depression affects one in 20 Austral-
ian teenagers, few of whom will access
specialist mental health services.7 Con-
trary to the view of Jureidini and
Tonkin, we believe general practitioners
must provide treatment for young peo-
ple suffering depression. A strength of
the National Health and Medical
Research Council guidelines is that they
offer comprehensive advice to promote
thoughtful assessment and management
of depression in young people.
1. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind,
randomized, placebo-controlled trial of fluoxetine in chil-
dren and adolescents with depression. Arch Gen Psychia-
try 1997; 54: 1031-1037.
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2. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine
in the treatment of adolescent major depression: a rand-
omized, controlled trial. J Am Acad Child Adolesc Psychia-
try 2001; 40: 762-772.
3. Keller MB, McCafferty JP. Paroxetine in the treatment of
major depression — reply [letter]. J Am Acad Child Ado-
lesc Psychiatry 2002; 41: 1270.
4. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo
response in studies of major depression: variable, substan-
tial and growing. JAMA 2002; 287: 1840-1847.
5. Harrington R, Whittaker J, Shoebridge P, Campbell F.
Systematic review of efficacy of cognitive behaviour thera-
pies in childhood and adolescent depressive disorder. BMJ
1998; 316: 1559-1563.
6. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine
for acute treatment of depression in children and adoles-
cents: a placebo-controlled, randomized clinical trial. J Am
Acad Child Adolesc Psychiatry 2002; 41: 1205-1215.
7. Rey JM, Sawyer MG, Clark JJ, Baghurst PA. Depression
among Australian adolescents. Med J Aust 2001; 175:
19-23. ❏
Measuring outcomes in 
patients with depression or 
anxiety: an essential part of 
clinical practice
Brian M Boettcher
Psychiatrist, Gold Coast Hospital, 108 Nerang Road, 
Southport, QLD 4215 bboettcher@ozemail.com.au
TO THE EDITOR: I do not believe that
Dinnen’s comments1 should be so eas-
ily dismissed as suggested by the aca-
demics  propos ing that  genera l
practitioners should do question-
naires,2,3 at least in New South Wales.
I write this as barely a month has
passed since a most damning report was
released by a NSW Parliamentary
Inquiry into Mental Health Delivery.
A prime example of arrogance and
loss of contact with the reality of clinical
services by academia and administra-
tion is that, during the demise of mental
health services in NSW, the services
have been forced to complete a new 30-
page admission process for every admis-
sion. Just what was needed by registrars
spending hours trying to find beds for
seriously mentally ill patients!
The gulf between academia and
administration on the one hand and
real clinical services on the other is
now huge in NSW, at least in mental
health services. No one outside real
clinical services has any credibility or
right to demand doctors, let alone
hard-pressed GPs, engage in dubious
and very likely useless research
projects without very special funding
to support the project.
I found the K10 questionnaire
extraordinarily simplistic compared
with a Mental State Examination
(MSE). Surely, if there is concern, doc-
tors should be encouraged to revise how
the MSE is carried out, and not encour-
aged to adopt “cookbook” medicine.
1. Dinnen A. Measuring outcomes in patients with depression
or anxiety: an essential part of clinical practice [letter]. Med
J Aust 2003; 178: 48.
2. Hickie IB, Andrews G, Davenport TA. Measuring outcomes
in patients with depression or anxiety: an essential part of
clinical practice. Med J Aust 2002; 177: 205-207.
3. Andrews GA, Hickie IB, Davenport TA. Measuring outcomes
in patients with depression or anxiety: an essential part of
clinical practice [letter]. Med J Aust 2003; 178: 48. ❏
Heidi Andersen-Dalheim
General Practitioner, Ivanhoe Medical Clinic, 
22 Livingstone Street, Ivanhoe, VIC 3079 
moldal@impaq.com.au
TO THE EDITOR: As a general practi-
tioner I was gratified to see Dinnen’s
letter1 in which he questioned the
“urgent need” for GPs to use more
questionnaires for depression manage-
ment. Reading the professorial reply,2 I
despair. As more and more specific
health promotions are introduced (eg,
Asthma 3-Step Plans, Diabetic Care
protocols, Health Assessments, Care
Plans) we have to consider not just our
patient’s problems, but which forms to
fill out or numbers to put down to fulfil
Health Insurance Commission require-
ments or be correctly remunerated.
By the time a depressed patient is
sitting in my room, he or she wants to
be correctly diagnosed and treated, not
to be given a form to fill out. In my
opinion, to hand a form to a depressed
patient who has tearfully told me his or
her problems is an insult. We do not
(yet) expect patients to fill out a check-
list for heart failure. As to the sugges-
tion that the form be filled out in the
waiting room, how is this to be done?
Should the patient be sent out again
with form in hand? Privacy concerns do
not allow reception staff to hand out
such forms, and the waiting room is not
the best place to fill them out if they are
needed. In reality, the GP is likely to
give the patient a form and then go have
a coffee or make a telephone call.
No psychiatrist will ever receive a
referral from me based on a K10 score.
I may, however, mention that my
patient still has suicidal impulses, cries a
lot, has trouble sleeping and cannot
concentrate at work. That should be
easy enough for anyone to understand.
1. Dinnen AH. Measuring outcomes in patients with depres-
sion and anxiety: an essential part of clinical practice
[letter]. Med J Aust 2003; 178: 48.
LETTERS
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2. Andrews G, Hickie IB, Davenport TA. Measuring outcomes
in patients with depression and anxiety: an essential part of
clinical practice [letter]. Med J Aust 2003; 178: 48. ❏
What is pathography?
Johan A Schioldann
Clinical Professor of Psychiatry, University of 
Adelaide, SA 5002 schioldann@senet.com.au
TO THE EDITOR: I read with great
interest about your search in dictionar-
ies for the word “pathography”.1
Pathography2 originates from reflec-
tions on genius and its possible associa-
tion with insanity, a question that has
occupied experts in many fields since
Socrates, Plato and Aristotle. The first
psychiatric scientific treatise concerning
this question was contributed by
Moreau de Tours in 1859.3 Inspired by
him, Cesare Lombroso, in 1863, coined
the famous expression genio et follia, and
contributed many, albeit somewhat
uncritical, pathographies.
The term pathography was first used
about 1899 by the German psychiatrist
Paul Julius Möbius, who contributed
with several seminal pathographies,
including Rousseau, Goethe, Schopen-
hauer and Nietzsche.
Among other famous pathographers
should be mentioned Freud, W Lange,
Jaspers, Birnbaum and Kretschmer.
Pathography can be defined4 as
. . . historical biography from a medi-
cal, psychological and psychiatric view-
point. It analyses a single individual’s
biological heredity, development, per-
sonality, life history, and mental and
physical pathology, within the socio-
cultural context of his/her time, in
order to evaluate the impact of these
factors upon his/her decision-making,
performance and achievements. No
preconceived format can be assumed
as the method depends on the nature of
the various available materials and on
the specific inquiry. A prerequisite for
plausible pathographical results is a
thorough knowledge and understand-
ing of psychopathology, and of the
borderland between normal and abnor-
mal mental life, combined with a
capacity for [sober] historical judge-
ment. . . . The pathographical method
is applicable to any personality, sick or
sound, provided that sufficient bio-
graphical sources are available. The
pathographical result is a facet but
often an indispensable one.
Subjects of pathography have tradi-
tionally been famous people in all areas
of human achievement. Pathography is
also indispensable in assisting histori-
ans, political scientists and other groups
in their quest for a better understanding
of events where leaders or other “very
important persons” have played a signif-
icant role, and where personality or
illness, physical or mental, has been
decisive, at times with far-reaching con-
sequences for nations.5,6 History is
replete with such examples.
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TO THE EDITOR: In the abstract of his
article on asthma prevention with die-
tary manipulation,1 Mellis states that
“we know” that the major modifiable
dietary environmental risk factors for
childhood asthma are not having been
breastfed and low intake of omega-3
fatty acids.
In his discussion of the evidence,
Mellis suggests that breastfeeding may
be protective and, impor tantly,
acknowledges the controversy. He fur-
ther states (in the abstract) that obser-
vational studies have shown a reduction
in childhood asthma in children who eat
fish regularly (that is, have a high intake
of omega-3 fatty acids), similar to those
who were exclusively breastfed for three
months. However, he provides no refer-
ences for these observational studies,
and nor does he discuss any specific
evidence in support of including omega-
3 fatty acids for reducing childhood
asthma.
While there are some suggestions of
such an association, the evidence is
extremely limited compared with the
extensive literature on the potential for
the protective effect of breastfeeding.
Further, there are substantial methodo-
logical issues associated with the few
studies that do exist, not the least of
which is the measurement of the rele-
vant dietary parameters.
Australian studies have suggested a
protective influence of at least two fish
meals per week on bronchial hyperre-
sponsiveness in 7–11-year olds2 and of
eating oily fish3 on the prevalence of
childhood asthma. However, neither of
these studies had the capacity to meas-
ure omega-3 fatty acid nor fish intake in
a valid way. These limitations were
acknowledged by the authors of the
studies, and have been noted by others;4
they need to be included in any discus-
sion of a putative protective effect. It
should also be noted that the biological
plausibility of such an association has
been challenged.4 There are many valid
reasons for promoting the consumption
of omega-3 fatty acids, but shouldn’t we
wait for the outcome of the randomised
clinical trial currently under way before
accepting the statement that “we know”
that a low intake of these fatty acids
increases the risk of childhood asthma?
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IN REPLY: Sherriff is correct in pointing
out that the studies showing protection
from bronchial asthma (and bronchial
hyperresponsiveness) are based on con-
sumption of fish meals rather than a
direct measure of omega-3 fatty acid
intake. This protection has been
observed consistently in cross-sectional
studies of New South Wales primary
school children. Thus, the level of evi-
dence is at best Level III, albeit using a
proxy for omega-3 fatty acid intake.
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Results of a randomised-controlled
trial of omega-3 fatty acid supplemen-
tation currently under way in western
Sydney are now in the public arena at
18-month follow-up.1,2 At this early
stage, it is uncertain who has genuine
asthma rather than other wheezing syn-
dromes. Nevertheless, the group who
received omega-3 fatty acid supplemen-
tation have differences in rates of
wheeze compared with those not sup-
plemented.1,2 For example, the rate of
“ever” having had wheeze was 52.6% in
the controls versus 42.8% in the sup-
plemented group (absolute risk reduc-
tion, 9.8%; number need to treat,
about 10).
In the table of recommendations in
my article,3 I carefully pointed out that
supplementing infants with omega-3
fatty acid is something to “consider”
rather than strongly recommending it.
It should also be noted the level of
evidence is low (Level III). Stronger
recommendations will depend on the
long-term results of randomised trials,
such as the western Sydney trial.1,2 In
summary, at this stage the only strong
dietary recommendations which can be
made are:
■ not to use strict elimination diets
during pregnancy (Level I evidence);
and
■ to consider using lactobacillus pro-
biotic supplements.
The evidence for lactobacillus is Level
II (from a single randomised controlled
trial), although the protection shown is
for atopy rather than asthma. Clearly,
the children in the lactobacillus study
will need further follow-up, and the trial
will need to be repeated in other popu-
lations.
All of this highlights the need for
better-quality studies in the area of pri-
mary prevention of asthma, based on
dietary factors during pregnancy or
early infancy.
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TO THE EDITOR: The publication of
the main results of the Antihypertensive
and Lipid-Lowering Treatment to Pre-
vent Heart Attack Trial (ALLHAT),
and the accompanying editorial, tri-
umph the role of thiazide diuretics as
first-line management for hyperten-
sion.1,2 It brought to mind the lines
from the nursery rhyme Old Mother
Hubbard — “And when she went there,
the cupboard was bare.”
Simple frequency analysis of diuretic
antihypertensive medications listed in
the Australian Medicines Handbook
(1998 and 2003) revealed that the
total number of thiazide diuretics




and in 2003 three (bendrofluazide,
chlorthalidone and indapamide).3,4
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